Pure ductal adenocarcinoma of the prostate (dPC) is thought to be found in just 0.4 to 0.8 percent of men who get diagnosed with prostate cancer each year. … READ MORE …
Filed under: Diagnosis, Drugs in development, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: adenocarcinoma, damage, DNA, ductal, homologous, mismatch, prostate, repair, sequencing | Leave a comment »
In this week’s Journal of Clinical Oncology, there is a full-text article in the “Comments and Controversies” section entitled … READ MORE …
Filed under: Uncategorized | Tagged: DNA, genetic, genomic, germline, test | 2 Comments »
By now, many readers have probably seen news reports coming out of Australia about the “possible medical breakthrough” of a rapid, highly accurate test that can be used to detect cancer anywhere in the body (prostate cancer specifically included). … READ MORE …
Filed under: Diagnosis, Management, Risk | Tagged: cancer, DNA, methylation, Methylscape, test | 2 Comments »
We have probably all heard terms like “liquid biopsy” and “genetic screening” and “cell-free” DNA analysis over the past few years. These are all terms related to the use of genetic and genomic information to “personalize” cancer diagnosis and its management. And they are potentially a huge big deal. But, … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: analysis, cancer, detection, DNA, Management, monitoring, risk | 4 Comments »
The American Society of Clinical Oncology (ASCO) and the College of Pathologists (CAP) have just issued a joint review of available information on clinical use of “liquid biopsies” to assess circulating levels of tumor DNA (ctDNA). … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: biopsy, circulating, ctDNA, DNA, liquid, review, test, tumor | 2 Comments »
In 2015, Inovio Pharmaceuticals started a Phase I trial of INO-5150 — a new type of immunotherapy using a DNA vaccine for prostate cancer which targets both prostate-specific antigen (PSA) and prostate-specific membrane antigen (PSMA). … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: biochemical, DNA, INO-5150, recurrence, Treatment, vaccine | Leave a comment »
A key question in management of prostate cancer is the risk that a particular patient has disease — at the time of diagnosis — that will progress over time to become metastatic. The ability to answer this question with accuracy is fundamental to the need for aggressive, early treatment. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: damage, DNA, pathway, profile, prognosis, repair | 4 Comments »
Regular readers of the medical science literature will be very conscious of the emphasis on genomic analysis of tumor specimens as a way to try to “personalize” treatment of cancers of many types — prostate cancer very specifically included. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: DNA, genome, individualized, medicine, personalized, sequencing, Treatment | 10 Comments »
According to a new article in the journal Clinical Chemistry, an international research team believes they have found a completely new way to test for risk of prostate cancer by measuring tumor-specific, cell-free DNA (cfDNA) in blood samples (serum and plasma). … READ MORE …
Filed under: Diagnosis, Risk | Tagged: Diagnosis, DNA, risk, test | 2 Comments »
As we become more knowledgeable about the underlying genetic and other factors that affect the risk for, and the risk for progression of, apparently localized prostate cancer, we also become more able to predict such risks … but this is a very complex topic. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: DNA, hypoxia, microenvironment, profile, prognosis, risk, tumor | 1 Comment »
According to a media release from the Mayo Clinic earlier today, “Alterations to the ‘on-off’ switches of genes occur early in the development of prostate cancer and could be used as biomarkers to detect the disease months or even years earlier than current approaches.” … READ MORE …
Filed under: Diagnosis, Management, Risk | Tagged: aggressiveness, DNA, expression, gene, methylation, test | 2 Comments »
According to a new paper in the journal Cell, researchers at the Sanger Institute at Cambridge, in England, believe they have discovered a completely new mechanism for the initial development of about 2 or 3 percent of all cancers. … READ MORE …
Filed under: Diagnosis, Risk | Tagged: cause, chromosome, chromothripsis, DNA, mutation | Leave a comment »
Elevated levels of free, circulating DNA (fcDNA) have previously been been found in the serum of prostate cancer patients compared with the levels in the serum of patients with benign prostate conditions. … READ MORE …
Filed under: Diagnosis, Risk | Tagged: biopsy, circulating, DNA, free, marker | 8 Comments »
THE "NEW" PROSTATE CANCER INFOLINK 